A study using the IDEAS amyloid PET registry assessed whether visual interpretations by community radiologists match expert panel assessments. Investigators selected about 1,500 routine scans for independent expert re-evaluation across the three FDA-approved tracers: 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol. The findings reported close agreement between local and expert readers, supporting the reliability of community practice interpretation as amyloid PET expands with Alzheimer’s disease therapeutic uptake and broader reimbursement. The analysis matters for health systems scaling imaging capacity, because variability in scan interpretation can directly affect patient classification and downstream treatment decisions. Going forward, demand for trained readers and standard reporting processes will likely intensify, but these results suggest many community settings may already be achieving expert-level concordance.